Eli Lilly Announces New Weight-Loss Drug Trial Results as Goldman Sachs Flags Market Optimism Above Historical Average

According to Jin10, Eli Lilly announced on June 8 that its next-generation weight-loss drug trial results showed potential to alleviate sleep apnea and other conditions. Separately, Goldman Sachs noted that U.S. stock market sentiment indicators have risen above historical averages, though still below peaks observed in 2000 and 2021.
Disclaimer: The information on this page may come from third-party sources and is for reference only. It does not represent the views or opinions of Gate and does not constitute any financial, investment, or legal advice. Virtual asset trading involves high risk. Please do not rely solely on the information on this page when making decisions. For details, see the Disclaimer.
Comment
0/400
No comments